6L9.F ViewRay (XETRA) +2400% to €0.025 on 09 Mar 2026: high-volume signal

6L9.F stock led intraday movers on XETRA after a +2400.00% jump to €0.025 on 09 Mar 2026, with volume at 3,500 shares versus an average of 279. The spike pushed the price above the day low of €0.001 and set a day high of €0.025. Traders should note that the move came on outsized relative volume of 12.54x, signalling speculative activity rather than a confirmed earnings catalyst. We explain the drivers, key ratios, and our short technical and fundamental read.

Price action and intraday drivers for 6L9.F stock

6L9.F stock moved from €0.001 to €0.025 early in the session on 09 Mar 2026, a €0.024 increase that produced the reported +2400.00% change. The trade volume at 3,500 shares was well above the average daily volume of 279, a classic high-volume mover pattern. This kind of spike often follows news, social volume, or low-float trading dynamics rather than improved fundamentals.

Fundamentals and valuation snapshot for 6L9.F stock

ViewRay, Inc. (6L9.F) trades on XETRA and reports trailing EPS of -0.55 and a negative PE of -0.05, reflecting consistent operating losses. Market capitalisation stands at approximately €207,228,256.00 with 8,289,130,240 shares outstanding. Price-to-book is 0.06, and current ratio is 2.36, showing short-term liquidity support despite negative margins.

Sector context: Healthcare and Medical – Devices impact on 6L9.F stock

6L9.F sits in Healthcare, industry Medical – Devices, where YTD sector performance is -1.16%. The sector’s average debt-to-equity is 0.75, while ViewRay’s debt-to-equity is around 1.05, which is higher than the sector mean. Weak sector performance adds pressure for recovery to be tied to commercial wins and product adoption in MR-guided therapy.

Technical and trading metrics behind the high-volume move

Short-term price averages show a 50-day mean of €0.32 and a 200-day mean of €2.72, both well above the current €0.025, indicating the stock remains in a long-term downtrend. Relative volume at 12.54x and a one-month change of +2400.00% reflect a short-term spike. Traders should watch liquidity, bid-ask spreads, and order-book depth after such moves.

Meyka AI stock grade and model context for 6L9.F stock

Meyka AI rates 6L9.F with a score of 61.44 out of 100 (Grade B, Suggestion: HOLD). This grade factors S&P 500 benchmark comparison, sector and industry comparison, financial growth, key metrics, forecasts, analyst consensus, and fundamental growth. The score reflects solid liquidity ratios but persistent losses and elevated debt levels. These grades are informational only and are not financial advice.

Risks, catalysts and what to watch next for 6L9.F stock

Primary risks include continued operating losses, an interest coverage ratio of -21.18, and past price volatility from €4.60 year high to €0.0005 year low. Catalysts that could sustain gains include new MRIdian system orders, regulatory updates, or positive clinical partnerships. Monitor company announcements and trading volume for confirmation before adding exposure.

Final Thoughts

Short-term, 6L9.F stock is a high-volume speculative mover after the intraday leap to €0.025 on 09 Mar 2026. Fundamentals show trailing EPS -0.55 and a negative PE, with market cap around €207,228,256.00 and a current ratio of 2.36, which cushions liquidity risk. Meyka AI’s forecast model projects €0.08 within 12 months, an implied upside of 220.00% versus the current €0.025, but this is model-based and not guaranteed. Given the Grade B / HOLD from Meyka AI and the stock’s long-term downtrend versus 50- and 200-day averages, we view any position as high risk and suited to traders who can absorb volatility. Keep watch on volume-confirmed follow-through, company news, and sector moves in Healthcare before treating this spike as a durable recovery.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.